Dry AMD: VALEDA Red Light Therapy
First retina practice in San Francisco offering VALEDA® for Dry AMD.
VALEDA® Light Delivery System is the first and only FDA-authorized treatment for Dry Age-Related Macular Degeneration (AMD) shown in clinical trials to improve visual acuity.
VALEDA utilizes photobiomodulation (PBM), delivering specific wavelengths of red light to retinal tissue to stimulate cellular energy production and support retinal cell function. By stimulating energy production in compromised cells, PBM helps improve cellular performance and may slow functional decline associated with Dry AMD.
In the LIGHTSITE III clinical trial, approximately 55% of treated patients gained at least five letters in visual acuity at 13 months, with data supporting both safety and sustained visual benefit.
Early diagnosis and ongoing monitoring are critical in managing Dry AMD. Our retina specialists provide individualized evaluation and treatment planning based on each patient’s clinical findings and risk factors to optimize long-term visual outcomes.
Each non-invasive treatment session is painless and typically completed in approximately 15 minutes.
Most patients complete their recommended treatment plan in an average of nine sessions.
Many patients begin to notice improvements in visual acuity and stabilization of AMD progression within five weeks.*
*Actual treatment plans and outcomes vary. Your retina specialist will review your diagnosis and discuss a personalized course of treatment with you.
Interested Valeda for Dry AMD treatment?
Schedule a consultation today to see if you may be a good candidate.
Learn More
Dry AMD
Dry AMD is a chronic retinal condition that causes gradual central vision loss due to degeneration of the macula. Visit the American Academy of Ophthalmology to learn more.
Retina
The retina is the light-sensitive tissue lining the back of the eye that enables vision. Learn more on our website about our services, treatments, and the retinal conditions we manage.
